معرفی
Dr. Ziv Gan-Or is an Associate Professor at The Neuro (Montreal Neurological Institute-Hospital), which is part of McGill University. He serves as the Executive Director of the Clinical Research Unit (CRU) and the Leader of the Neurodegenerative Disorders Research Group. Dr. Gan-Or also leads the GBA1 Canada initiative (G-CAN) and the Neurogenomics and Precision Medicine lab (NAP-Med).
Dr. Gan-Or completed his MD and PhD at Tel-Aviv University, Israel, with a major interest in lysosomal related genes and their role in the pathogenesis and progression of Parkinson's Disease and other neurodegenerative disorders.
Dr. Gan-Or's research primarily focuses on the genetics of neurodegenerative disorders, particularly Parkinson's Disease and REM Sleep Behavior Disorder (RBD). His lab uses advanced multi-omic approaches to study the effects of genetics on risk, progression and response to medications in neurodegenerative disorders. A major focus is understanding how genetic background affects the conversion from RBD to neurodegenerative diseases like Parkinson's Disease, dementia with Lewy bodies, or multiple system atrophy. His work aims to identify novel pathways and mechanisms that may help develop treatments for these conditions.
Analysis of Dr. Gan-Or's recent publications (2020-2024) reveals a strong emphasis on genetic factors in Parkinson's disease and related disorders. His research spans multiple areas including lysosomal biology (CTSB, GBA1, GALC genes), population genetics across diverse ethnic groups, functional analysis of disease-associated variants, and the application of machine learning to identify novel pathways. His work frequently involves large international collaborations, with studies incorporating data from dozens of research centers worldwide.
- Killam Scholar
Dr. Gan-Or leads the Neurogenomics and Precision Medicine lab (NAP-Med) and the International RBD Genomics Consortium, which includes the world's largest cohort of RBD patients. His lab collaborates with over 60 collaborators worldwide, providing a unique, supportive and stimulating environment for trainees. He is actively involved in multiple research initiatives including the GBA1 Canada initiative (G-CAN), which aims to accelerate the development of treatments for GBA1-associated neurodegeneration.
